Envista (NYSE:NVST) & BioLife Solutions (NASDAQ:BLFS) Head-To-Head Contrast

Envista (NYSE:NVST) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Envista and BioLife Solutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	2	8	5	1	2.31
BioLife Solutions	1	1	4	0	2.50

Envista currently has a consensus target price of $21.77, suggesting a potential downside of 0.68%. BioLife Solutions has a consensus target price of $31.00, suggesting a potential upside of 25.71%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Envista.

Volatility and Risk

Envista has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Institutional and Insider Ownership

93.2% of BioLife Solutions shares are held by institutional investors. 0.7% of Envista shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Envista and BioLife Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envista	0.58%	5.90%	3.25%
BioLife Solutions	-3.20%	0.97%	0.87%

Earnings and Valuation

This table compares Envista and BioLife Solutions”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.51 billion	1.44	-$1.12 billion	$0.09	243.54
BioLife Solutions	$100.14 million	11.86	-$20.18 million	($0.07)	-352.29

BioLife Solutions has lower revenue, but higher earnings than Envista. BioLife Solutions is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Summary

Envista beats BioLife Solutions on 8 of the 15 factors compared between the two stocks.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.